These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 31325268

  • 1. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR, Marathe PA.
    J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
    [Abstract] [Full Text] [Related]

  • 2. Undergraduate Medical Teaching: Time to integrate?
    Ravikirti, Sharma S.
    J Assoc Physicians India; 2018 Aug; 66(8):85-86. PubMed ID: 31324092
    [Abstract] [Full Text] [Related]

  • 3. Delamanid: first global approval.
    Ryan NJ, Lo JH.
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [Abstract] [Full Text] [Related]

  • 4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS, Jeong BH, Koh WJ.
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [Abstract] [Full Text] [Related]

  • 5. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R, Geiter L, Hafkin J.
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [Abstract] [Full Text] [Related]

  • 6. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R, Soni I, Dasgupta A, Chopra S.
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [Abstract] [Full Text] [Related]

  • 7. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD.
    N Engl J Med; 2012 Jun 07; 366(23):2151-60. PubMed ID: 22670901
    [Abstract] [Full Text] [Related]

  • 8. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G, Pontali E, Centis R, D'Ambrosio L, Migliori GB.
    Expert Rev Anti Infect Ther; 2015 Mar 07; 13(3):305-15. PubMed ID: 25645397
    [Abstract] [Full Text] [Related]

  • 9. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA, Scott LJ.
    Drugs; 2015 Jan 07; 75(1):91-100. PubMed ID: 25404020
    [Abstract] [Full Text] [Related]

  • 10. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD, Lynch JB.
    Drug Des Devel Ther; 2015 Jan 07; 9():677-82. PubMed ID: 25678771
    [Abstract] [Full Text] [Related]

  • 11. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 07; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 13. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
    Luo W, Huang Z, Xu D, Yang M, Zhu Y, Shen L, Chen S, Tao X, Bin W, Hu Y, Franzblau SG, Jiang N, Wei Y, Wei X, Ding CZ.
    Bioorg Med Chem Lett; 2022 Sep 15; 72():128871. PubMed ID: 35777718
    [Abstract] [Full Text] [Related]

  • 14. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
    BMC Infect Dis; 2019 Aug 20; 19(1):733. PubMed ID: 31429722
    [Abstract] [Full Text] [Related]

  • 15. Six-Month Response to Delamanid Treatment in MDR TB Patients.
    Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A, Vambe D, Vasilyeva I, Lachenal N, Varaine F.
    Emerg Infect Dis; 2017 Oct 20; 23(10):1746-8. PubMed ID: 28767036
    [Abstract] [Full Text] [Related]

  • 16. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Expert Opin Pharmacother; 2015 Oct 20; 16(18):2737-50. PubMed ID: 26478945
    [Abstract] [Full Text] [Related]

  • 17. Delamanid in the treatment of multidrug-resistant tuberculosis.
    Gupta R, Wells CD, Hittel N, Hafkin J, Geiter LJ.
    Int J Tuberc Lung Dis; 2016 Dec 01; 20(12):33-37. PubMed ID: 28240570
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
    Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.
    Emerg Infect Dis; 2017 Oct 01; 23(10):1718-21. PubMed ID: 28758888
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline and delamanid in tuberculosis.
    Esposito S, Bianchini S, Blasi F.
    Expert Opin Pharmacother; 2015 Oct 01; 16(15):2319-30. PubMed ID: 26293803
    [Abstract] [Full Text] [Related]

  • 20. Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis.
    Chen X, Hashizume H, Tomishige T, Nakamura I, Matsuba M, Fujiwara M, Kitamoto R, Hanaki E, Ohba Y, Matsumoto M.
    Antimicrob Agents Chemother; 2017 Jun 01; 61(6):. PubMed ID: 28373190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.